Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
about
Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphomaAllogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphomaCutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and managementMycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.Unique Presentation of Leukemic Cutaneous CD3/TCR- Phenotype T-Cell Lymphoma with Complete Remission after Allogeneic Stem Cell Transplantation.Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndromeSkin Recurrence of Transformed Mycosis Fungoides Postumbilical Cord Blood Transplant despite Complete Donor Chimerism.Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas.Follow-up of patients with mycosis fungoides after interferon α2b treatment failure.Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomasAllogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institutionMenus for managing patients with cutaneous T-cell lymphoma.Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.Allogeneic hematopoietic stem cell transplantation in mycosis fungoides.Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas.Treatment algorithms for mature T-cell and natural killer-cell neoplasms.Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.Cutaneous T-cell lymphomas: a review of new discoveries and treatments.Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.Cutaneous T cell lymphoma: update on treatment.Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current statusNovel therapies for cutaneous T-cell lymphoma: what does the future hold?Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?New and established treatment options for mycosis fungoides and Sézary syndrome - an update.Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma.The utility of bexarotene in mycosis fungoides and Sézary syndrome.Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.Hematopoietic stem cell transplantation for cutaneous T-cell lymphoma: Summary of 11 cases from two facilities in Japan and Brazil.Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma.Reduced-intensity conditioning followed by cord blood transplantation in a patient with refractory folliculotropic mycosis fungoides.Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
P2860
Q24200183-58A016FD-B67B-44B0-9741-398D6F96A953Q24203887-7B960155-AA2D-4746-95B4-619E3CBD6C50Q27024076-8B294750-AFD3-43E0-9BDF-6DF25D38C4DEQ30252152-80C22515-9EA2-4DE3-8A84-8EC159F7825FQ33716514-0284771F-7FB6-4B0E-A7CC-E4D159648551Q34459010-A05C8D9E-BAE9-49D8-9D12-89F003A2108DQ34785645-6D722B01-7A53-4444-B359-32C907A41365Q35022833-30AE6D23-2D9D-4A26-87A0-A25DE09D1197Q35087581-69250B3F-00EF-4EFC-84F7-708D1C703110Q35620524-C131BDBB-FB62-4049-8CDA-8B3BD7123087Q36231758-F7382D08-62EC-41BC-9FB9-89CB78A85D91Q36470196-D6726990-97FA-4D3E-9AF3-E8E07BC9D020Q36491117-161F9C15-0127-4086-BA3F-769CD0E79572Q36865042-81DDC29C-C1AB-48A0-B390-2223D542DE58Q36934406-369D8F0B-F087-4D97-83C2-A03EC999CD31Q37323004-EB80E754-E97F-43BE-9EA4-CBB872981806Q37420625-66E62130-1800-426D-890C-34CDBE9A4B61Q37618920-CBB0012C-F1E9-4874-B766-1321E4A8A2B3Q37932546-1918E298-67CF-4C00-981E-EFE79DA11D02Q37938531-7D80BD24-03E3-4E92-9090-A0BDD1384FE3Q37944565-0F6737E7-75FD-40A2-AB8B-305842C5AC1BQ37981969-E3DEA43D-B88C-42B7-B3DF-91A85925E9B6Q37998019-0CB1E1CD-845E-4AB3-8C50-354768AA951BQ38036396-1DC0BE6F-47C2-443F-AB09-2F80338FB668Q38042561-434054EB-610D-41CE-8E47-E466AA633DBEQ38108320-8D30E39E-6F8D-4070-8B56-05F93B40BDFBQ38176398-AEC0AF65-D5B4-4F81-B32B-C5FB615E2DCEQ38196931-B65F1274-EBE7-4C82-99D9-FD90DBFA67B9Q38216976-0982874F-B669-4BC2-A8DF-78C979798495Q38286313-A655333B-A6CA-4C2D-9FD9-D9EDA79FF435Q38354440-9C657D86-EEBF-4FE4-B515-0A785B9A3EEEQ38387292-3246C44C-B176-461A-B65F-DD415C9E9F11Q38765889-EBEE7B65-A31D-4665-B48E-72305CC05DFDQ41099857-80C49401-396E-458D-8C90-9CE1D2869917Q41106212-40810EF9-E4E6-455D-92FA-A086103636ECQ42232495-D16746B2-8BA9-4AAE-8171-D0C3D66537B1Q43444250-3FAEB43E-3F5F-4591-85D0-406EB4A55918Q46228976-7CEF0163-F6E3-4A6C-8353-263E81F8EB52Q48034709-0480AC92-2EE6-448F-BE8C-01918D36FBA2Q48296904-99B98AF0-5AE3-431E-B249-6CCFBBCCD1C4
P2860
Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Allogeneic hematopoietic cell ...... od and Marrow Transplantation.
@en
Allogeneic hematopoietic cell ...... od and Marrow Transplantation.
@nl
type
label
Allogeneic hematopoietic cell ...... od and Marrow Transplantation.
@en
Allogeneic hematopoietic cell ...... od and Marrow Transplantation.
@nl
prefLabel
Allogeneic hematopoietic cell ...... od and Marrow Transplantation.
@en
Allogeneic hematopoietic cell ...... od and Marrow Transplantation.
@nl
P2093
P356
P1476
Allogeneic hematopoietic cell ...... ood and Marrow Transplantation
@en
P2093
Anna Sureda
Augustin Ferrant
Carmen Canals
Eduardo Olavarría
Francesco Onida
Giorgio Lambertenghi Deliliers
Guido Kobbe
Ian H Gabriel
Norbert Schmitz
Rafael F Duarte
P304
P356
10.1200/JCO.2010.29.3241
P407
P577
2010-08-09T00:00:00Z